

Consumer Medicine Information (CMI) summary

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist.

1. Why am I using Skyrizi?

Skyrizi contains the active ingredient risankizumab. Skyrizi is used to treat moderate to severe plaque psoriasis, active psoriatic arthritis, moderate to severe ulcerative colitis in adults, and moderate to severe Crohn's disease in patients from 16 years of age. For more information, see Section 1. Why am I using Skyrizi? in the full CMI.

2. What should I know before I use Skyrizi?

Check the list of ingredients at the end of the CMI. Do not use Skyrizi if you have ever had an allergic reaction to any of them.

Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or are breastfeeding.

For more information, see Section 2. What should I know before I use Skyrizi? in the full CMI.

3. What if I am taking other medicines?

Some medicines may interfere with Skyrizi and affect how it works or Skyrizi may interfere with other medicines and affect how they work.

A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI.

4. How do I use Skyrizi?

Skyrizi is injected under the skin. More instructions can be found in Section 4. How do I use Skyrizi? in the full CMI.

5. What should I know while using Skyrizi?

Things you should do	 Ensure you are up to date with your immunisations <u>before</u> you start therapy with Skyrizi. Speak to your doctor if you think you have an infection. Remind any doctor, dentist or pharmacist you visit that you are using Skyrizi. 	
Things you should not do	Do not stop using this medicine or change the dose without checking with your doctor.	
Driving or using machines	Skyrizi is not expected to have any effect on your ability to drive or use machines.	
Drinking alcohol	alcohol • There is no information on the effects of using Skyrizi with alcohol.	
Looking after your medicine	 Store Skyrizi in the refrigerator at 2°C to 8°C. Do not freeze. Keep it in the original carton until it's time to inject it to protect it from light. 	

For more information, see Section 5. What should I know while using Skyrizi? in the full CMI.

6. Are there any side effects?

The very serious side effects include: Symptoms of a possible serious allergic reaction (anaphylaxis) including difficulty breathing or swallowing, swelling of the face, lips, tongue or throat, severe itching of the skin with a red rash or raised bumps, low blood pressure, which can cause dizziness, feeling faint or lightheadedness.

The more serious side effects include: Symptoms of a serious infection, including fever, flu-like symptoms, night sweats, feeling tired or short of breath, a cough that won't go away, warm, red, painful skin or painful rash with blisters.

The more common side effects include: upper respiratory infections with symptoms such as sore throat and stuffy nose, tiredness, headache, injection site reactions, itching, fungal skin infection.

For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI.

Skyrizi® CMI v10 DS v12 4 December 2024 Page 1 of 5



Active ingredient: risankizumab (ri-zan-ki-zyu-mab)

Consumer Medicine Information (CMI)

This leaflet provides important information about using Skyrizi. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using Skyrizi.

Where to find information in this leaflet:

- 1. Why am I using Skyrizi?
- 2. What should I know before I use Skyrizi?
- 3. What if I am taking other medicines?
- 4. How do I use Skyrizi?
- 5. What should I know while using Skyrizi?
- 6. Are there any side effects?
- 7. Product details

1. Why am I using Skyrizi?

Skyrizi contains the active ingredient risankizumab which is a type of protein called a monoclonal antibody. It works by stopping a protein in the body called IL-23 which causes inflammation.

Psoriasis: Skyrizi reduces inflammation and can therefore help to improves skin clearance and the appearance of nails. It also reduces symptoms of plaque psoriasis such as burning, itching, pain, redness and scaling.

Psoriatic Arthritis: Skyrizi reduces the inflammation and can therefore help to reduce pain, stiffness and swelling in and around your joints, pain and stiffness in your spine, psoriatic skin rash, psoriatic nail damage and it may limit damage to the bone and cartilage in your joints. These effects can ease your normal daily activities, reduce tiredness and improve your quality of life.

Crohn's Disease: Skyrizi reduces the inflammation and can therefore help to reduce signs and symptoms such as abdominal pain, diarrhoea and tiredness, and improve healing of your bowel, which can help improve your quality of life.

Ulcerative Colitis: Skyrizi reduces inflammation and can therefore help to reduce signs and symptoms of your disease such as abdominal pain, bloody stools, frequent and loose stools, and tiredness, as well as improve healing of the bowel, which can help improve your quality of life.

2. What should I know before I use Skyrizi?

Warnings

Do not use Skyrizi if:

- you are allergic to risankizumab, or any of the ingredients listed at the end of this leaflet.
- 2. you have an infection considered by your doctor to need special attention.

Check with your doctor if you:

- have an infection now
- have had an infection that keeps coming back
- have or have had tuberculosis
- have had a recent vaccination or are scheduled for any immunisations
- take any medicines for any other condition

During treatment, you may be at risk of developing certain side effects. It is important you understand these risks and how to monitor for them. See additional information under Section <u>6</u>. Are there any side effects?

Pregnancy and breastfeeding

Make sure your doctor is aware that you are pregnant or plan to become pregnant or are breastfeeding or plan to do so.

Children

- Psoriasis, Psoriatic Arthritis, and Ulcerative Colitis: Skyrizi is not recommended for children younger than 18 years.
- Crohn's Disease: Skyrizi is not indicated for patients under the age of 16 years. Therefore, Skyrizi is not recommended for children under this age.

3. What if I am taking other medicines?

Tell your doctor or pharmacist if you are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop.

Do this even though Skyrizi is not expected to be affected by other medicines, nor is it expected to interfere with other medicines.

4. How do I use Skyrizi?

How much to use

Psoriasis and Psoriatic Arthritis

The dose is 150 mg. After the first dose, you will have the next dose 4 weeks later and then every 12 weeks. If using the 150 mg/mL pre-filled syringe or pre-filled pen, each dose is given as one 150 mg injection. If using the 75 mg/0.83 mL pre-filled syringe, each dose is given as two 75 mg injections.

Skyrizi® CMI v10 DS v12 4 December 2024 Page 2 of 5

Crohn's Disease and Ulcerative Colitis

You will begin treatment with Skyrizi with a starting dose (known as induction phase) which will be given to you by your doctor, nurse, or healthcare professional through a drip in your arm (intravenous infusion).

Starting doses

	How much?	When?
Crohn's disease	600 mg	Week 0 (When your doctor tells you)
	600 mg	Week 4 (4 weeks after your first starting dose)
	600 mg	Week 8 (4 weeks after your second starting dose)
Ulcerative colitis	1200 mg	Week 0 (When your doctor tells you)
	1200 mg	Week 4 (4 weeks after your first starting dose)
	1200 mg	Week 8 (4 weeks after your second starting dose)

Afterwards, you will receive, or you will be able to inject Skyrizi using a pre-filled cartridge with an on-body injector as an injection under your skin (subcutaneous injection).

Maintenance doses

	How much?		When?
Crohn's disease	First maintenance dose	360 mg	Week 12 (4 weeks after the last starting dose)
	Further doses	360 mg	Week 20 and every 8 weeks, starting after the first maintenance dose
Ulcerative colitis	First maintenance dose	180 mg or 360 mg	Week 12 (4 weeks after the last starting dose)
	Further doses	180 mg or 360 mg	Week 20 and every 8 weeks, starting after the first maintenance dose

Follow all the instructions given to you and continue to use Skyrizi until your doctor tells you to stop.

How to inject Skyrizi

Skyrizi 75 mg/0.83 mL pre-filled syringe, 150 mg/mL pre-filled syringe or pen, 180 mg/1.2 mL pre-filled cartridge with on-body injector and 360 mg/2.4 mL pre-filled cartridge with on-body injector are injected under your skin (subcutaneous injection).

- It can be injected by the patient or by someone else, such as a family member, friend or carer.
- An injection should not be attempted until proper training has been received on the correct injection technique.
- Read the instructions for preparing and giving a Skyrizi injection that are supplied with the product.

Skyrizi 600 mg/10 mL

- Skyrizi 600 mg/10 mL single-use vial for intravenous infusion will be given by your doctor, nurse or healthcare professional through a vein in your arm (intravenous infusion).
- Skyrizi 600 mg/ 10 mL should be prepared and given by a healthcare professional using aseptic technique.

Click on the link for the instructions on how to inject 75 mg/0.83mL pre-filled syringe:

https://www.medsinfo.com.au/media/veisky75

Click on the link for the instructions on how to inject 150 mg/ mL pre-filled syringe:

https://www.medsinfo.com.au/media/veis150s

Click on the link for the instructions on how to inject 150 mg/mL pre-filled pen:

https://www.medsinfo.com.au/media/veis150p

Click on the link for the instructions on how to inject using the 180 mg/1.2 mL pre-filled cartridge with on-body injector:

https://www.medsinfo.com.au/media/veipfcx2

Click on the link for the instructions on how to inject using the 360 mg/2.4 mL pre-filled cartridge with on-body injector:

https://www.medsinfo.com.au/media/veipfcx2

Please look for the QR code on the medicine pack. Scan this code with your smart phone for more information on Skyrizi.

If you forget to inject Skyrizi

It is important that you use your medicine as instructed.

If you miss your dose at the usual time, inject Skyrizi as soon as you remember, and continue injecting the next dose at the usual time on your next scheduled day.

Do not inject a double dose to make up for the dose you missed.

Skyrizi® CMI v10 DS v12 4 December 2024 Page 3 of 5

If you inject too much Skyrizi

You should immediately:

- phone the National Poisons Centre (by calling 0800 POISON or 0800 764 766) or
- contact your doctor, or
- go to the Emergency Department at your nearest hospital.

You should do this even if there appear to be no signs of discomfort or poisoning.

5. What should I know while using Skyrizi?

Things you should do

- Ensure you are up to date with your immunisations before you start therapy with Skyrizi
- Keep all your doctor's appointments so your progress can be tracked.

Call your doctor straight away if you:

· Become pregnant while using Skyrizi.

Remind any doctor, dentist or pharmacist you visit that you are using Skyrizi.

Things you should not do

- Do not inject Skyrizi if the liquid looks cloudy or contains flakes or large particles.
- Do not stop using this medicine or change the dose without checking with your doctor.

Driving or using machines

Skyrizi is not expected to have any effect on your ability to drive or use machines.

Drinking alcohol

There is no information on the effects of using Skyrizi with alcohol.

Looking after your medicine

Follow the instructions on the carton on how to take care of your medicine properly.

- Keep Skyrizi in the refrigerator (at 2°C to 8°C). Do not freeze.
- Keep in the original carton to protect it from light.

If needed, you may also store Skyrizi 150 mg/mL pen or pre-filled syringe, Skyrizi 180 mg/1.2 mL or 360 mg/2.4 mL pre-filled cartridge with on-body injector one time out of the refrigerator (up to a maximum of 25°C) for up to 24 hours in the original carton to protect from light.

If unopened and stored below 25°C for less than 24 hours, you may return the Skyrizi 150 mg/mL pen or pre-filled syringe or 180 mg/1.2 mL or 360 mg/2.4 mL pre-filled cartridge with on-body injector to the refrigerator.

The pre-filled syringe can be taken out of the fridge 15 to 30 minutes before injected, provided it is kept in the carton. This may make the injection more comfortable.

The pre-filled pen can be taken out of the fridge 30 to 90 minutes before injected, provided it is kept in the carton.

The pre-filled cartridge with on-body injector can be taken out of the fridge to reach room temperature for 45 to 90 minutes before injected, provided they are kept in the carton. Keep out of direct sunlight.

Do not use this medicine after the expiry date.

Keep it where young children cannot reach it.

When to discard your medicine

Throw away the used syringe, pen or on-body injector immediately after injecting, as instructed by your doctor or nurse.

Getting rid of any unwanted medicine

If you no longer need to use this medicine or it is out of date, take it to any pharmacy for safe disposal.

6. Are there any side effects?

All medicines can have side effects. If you do experience any side effects, most of them are minor and temporary. However, some side effects may need medical attention.

See the information below and, if you need to, ask your doctor or pharmacist if you have any further questions about side effects.

Less serious side effects

Less serious side effects	What to do
 Upper respiratory tract infection: sore throat stuffy nose 	Speak to your doctor if you have any of these less
 Skin: fungal skin infection, such as athlete's foot (tinea) pain, or redness at the injection site small raised red bumps on the skin 	serious side effects and they worry you.
General:headachefeeling especially tired	

Skyrizi® CMI v10 DS v12 4 December 2024 Page 4 of 5

More serious side effects

More serious side effects	What to do
Signs of a serious infection: fever flu-like symptoms night sweats feeling tired or short of breath cough that won't go away warm, red painful skin painful skin rash with small red blisters	Call your doctor straight away, if you notice any of these serious side effects.

Very serious side effects

Very serious side effects	What to do
 Signs of a serious allergic reaction (anaphylaxis): difficulty breathing or swallowing swelling of face, lips, tongue or throat severe itching of skin, with a red rash or raised bumps low blood pressure, which can cause dizziness, feeling faint or lightheadedness 	Go straight to the Emergency Department at your nearest hospital if you notice any of these very serious side effects.

Tell your doctor or pharmacist if you notice anything else that may be making you feel unwell.

Other side effects not listed here may occur in some people.

Always make sure you speak to your doctor or pharmacist before you decide to stop taking any of your medicines.

7. Product details

This medicine is only available with a doctor's prescription.

What Skyrizi contains

Active ingredient	risankizumab	
(main ingredient)		
Other ingredients 75 mg/0.83 mL (inactive ingredients)	 sodium succinate hexahydrate succinic acid sorbitol polysorbate 20 water for injections 	
Other ingredients 150 mg/mL, 180 mg/1.2 mL,	 sodium acetate trihydrate glacial acetic acid trehalose dihydrate polysorbate 20 	

360 mg/2.4 mL and 600 mg/10 mL	•	water for injections
(inactive ingredients)		

Do not take this medicine if you are allergic to any of these ingredients.

Skyrizi contains 34 mg sorbitol in each 75 mg/0.83mL injection.

Not all presentations may be marketed.

What Skyrizi looks like

Skyrizi 75 mg/0.83 mL is a colourless to slightly yellow liquid and is supplied in a pre-filled syringe with needle guard. The liquid may contain tiny white or clear particles. Do not use if liquid is cloudy or contains flakes or large particles. Two syringes are supplied per carton. The carton also contains two alcohol pads.

Skyrizi 150 mg/mL liquid should look clear to yellow and may contain tiny white or clear particles. Do not inject if the liquid is cloudy or contains flakes or large particles. It is supplied in a 150 mg/mL pre-filled syringe with needle guard or a 150 mg/mL pre-filled pen. Each carton contains one pre-filled syringe or one pre-filled pen.

Skyrizi 180 mg/1.2 mL and 360 mg/2.4 mL liquid should look clear and colourless to yellow and may contain tiny white or clear particles in a pre-filled cartridge with onbody injector. Do not inject if the liquid is cloudy or contains flakes or large particles. It is supplied in a 180 mg/1.2 mL pre-filled cartridge with on-body injector or a 360 mg/2.4 mL pre-filled cartridge with on-body injector. Each carton contains one pre-filled cartridge and one on-body injector (180 mg/1.2 mL or 360 mg/2.4 mL).

Skyrizi 600 mg/ 10 mL liquid should look clear and colourless to slightly yellow and may contain tiny white or clear particles in a single-use vial. Do not inject if the liquid is cloudy or contains flakes or large particles. Each carton contains one vial.

Who distributes Skyrizi?

SKYRIZI is distributed in New Zealand by:

AbbVie Limited

6th Floor, 156-158 Victoria Street

Wellington 6011

New Zealand

This leaflet was prepared in December 2024.

Version 10

© 2024 AbbVie. All rights reserved. SKYRIZI® is a registered trademark of AbbVie Biotechnology Ltd.

Skyrizi® CMI v10 DS v12 4 December 2024 Page 5 of 5